These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33813001)

  • 1. Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase.
    Wang CJ; Li D; Danielson JA; Zhang EH; Dong Z; Miller KD; Li L; Zhang JT; Liu JY
    Cancer Lett; 2021 Jul; 509():1-12. PubMed ID: 33813001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Activity of the Lansoprazole Metabolite 5-Hydroxy Lansoprazole Sulfide in Triple-Negative Breast Cancer by Inhibiting the Enoyl Reductase of Fatty Acid Synthase.
    Beebe J; Josephraj S; Wang CJ; Danielson J; Cui Q; Huang C; Barlow L; Zhang RH; Zhang T; Nakshatri H; Dong Z; Li X; Liu JY; Zhang JT
    J Med Chem; 2022 Oct; 65(20):13681-13691. PubMed ID: 36257066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase.
    Fako VE; Wu X; Pflug B; Liu JY; Zhang JT
    J Med Chem; 2015 Jan; 58(2):778-84. PubMed ID: 25513712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.
    Corominas-Faja B; Vellon L; Cuyàs E; Buxó M; Martin-Castillo B; Serra D; García J; Lupu R; Menendez JA
    Histol Histopathol; 2017 Jul; 32(7):687-698. PubMed ID: 27714708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.
    Yu M; Lee C; Wang M; Tannock IF
    Cancer Sci; 2015 Oct; 106(10):1438-47. PubMed ID: 26212113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells.
    Yan C; Wei H; Minjuan Z; Yan X; Jingyue Y; Wenchao L; Sheng H
    PLoS One; 2014; 9(5):e97697. PubMed ID: 24866893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
    Menendez JA; Mehmi I; Papadimitropoulou A; Vander Steen T; Cuyàs E; Verdura S; Espinoza I; Vellon L; Atlas E; Lupu R
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FASN negatively regulates p65 expression by reducing its stability via Thr
    Barlow L; Josephraj S; Gu B; Dong Z; Zhang JT
    J Lipid Res; 2024 Apr; 65(4):100529. PubMed ID: 38467328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FASN inhibition as a potential treatment for endocrine-resistant breast cancer.
    Gruslova A; McClellan B; Balinda HU; Viswanadhapalli S; Alers V; Sareddy GR; Huang T; Garcia M; deGraffenried L; Vadlamudi RK; Brenner AJ
    Breast Cancer Res Treat; 2021 Jun; 187(2):375-386. PubMed ID: 33893909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the development of fatty acid synthase inhibitors as anticancer targets.
    Mullen GE; Yet L
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4363-9. PubMed ID: 26364942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
    Puig T; Aguilar H; Cufí S; Oliveras G; Turrado C; Ortega-Gutiérrez S; Benhamú B; López-Rodríguez ML; Urruticoechea A; Colomer R
    Breast Cancer Res; 2011; 13(6):R131. PubMed ID: 22177475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression.
    Ventura R; Mordec K; Waszczuk J; Wang Z; Lai J; Fridlib M; Buckley D; Kemble G; Heuer TS
    EBioMedicine; 2015 Aug; 2(8):808-24. PubMed ID: 26425687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyridine derivatives as anticancer lead compounds with Fatty Acid Synthase as the target: An in silico-guided in vitro study.
    Amrutha NA; Archana PR; Mohan SG; Anto RJ; Sadasivan C
    J Cell Biochem; 2019 Oct; 120(10):16643-16657. PubMed ID: 31095793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells.
    Ihraiz WG; Ahram M; Bardaweel SK
    Acta Pharm; 2020 Jun; 70(2):179-190. PubMed ID: 31955147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer.
    Wang J; Zhang X; Shi J; Cao P; Wan M; Zhang Q; Wang Y; Kridel SJ; Liu W; Xu J; Zhang Q; Sui G
    Oncotarget; 2016 Nov; 7(48):78566-78576. PubMed ID: 27713175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells.
    Vazquez-Martin A; Ropero S; Brunet J; Colomer R; Menendez JA
    Oncol Rep; 2007 Oct; 18(4):973-80. PubMed ID: 17786362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docosahexaenoic acid reduces sterol regulatory element binding protein-1 and fatty acid synthase expression and inhibits cell proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line.
    Huang LH; Chung HY; Su HM
    BMC Cancer; 2017 Dec; 17(1):890. PubMed ID: 29282029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.
    Hill TK; Davis AL; Wheeler FB; Kelkar SS; Freund EC; Lowther WT; Kridel SJ; Mohs AM
    Mol Pharm; 2016 Mar; 13(3):720-8. PubMed ID: 26824142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PdpaMn inhibits fatty acid synthase-mediated glycolysis by down-regulating PI3K/Akt signaling pathway in breast cancer.
    Okrah EA; Wang Q; Fu H; Chen Q; Gao J
    Anticancer Drugs; 2020 Nov; 31(10):1046-1056. PubMed ID: 32649369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acid synthase overexpression confers an independent prognosticator and associates with radiation resistance in nasopharyngeal carcinoma.
    Kao YC; Lee SW; Lin LC; Chen LT; Hsing CH; Hsu HP; Huang HY; Shiue YL; Chen TJ; Li CF
    Tumour Biol; 2013 Apr; 34(2):759-68. PubMed ID: 23208675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.